A drug discovery platform to identify compounds that inhibit EGFR triple mutants
February 24th, 2020 by Punit Saraon
Nature Chemical Biology, Published online: 24 February 2020; doi:10.1038/s41589-020-0484-2
A high-throughput small-molecule drug screening platform enabled the detection of compounds targeting the functional interactions of receptor tyrosine kinases and identifies four new EGFR triple-mutant inhibitors.